Reflecting bioCSL's longstanding commitment to public health and improving seasonal influenza vaccination rates, bioCSL Inc. will deliver about 16.5 million doses of the 2014-2015 formulation of AFLURIA, with approximately 75 percent of doses in thimerosal-free pre-filled syringes.
"Our historical operational focus on early and consistent delivery has resulted in a strong customer prebook order demand for the coming season," said Dr.
The impact of the 2013-14 influenza season was especially detrimental to the health of 18-64 year old adults. Approximately 60 percent of the reported influenza-associated hospitalizations were among people between the ages of 18 and 64. While the
"With each influenza season comes new challenges," said Dr. Mazur. "The flu is a significant public health threat. bioCSL Inc. strives to deliver vaccines to providers as early as possible to give them ample time to vaccinate against the flu." About AFLURIAŽ AFLURIA is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza virus subtypes A and type B present in the vaccine. AFLURIA is approved for use in persons 5 years of age and older. Select Safety Information AFLURIA is contraindicated in individuals with known severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine including egg protein, or to a previous dose of any influenza vaccine.
If Guillain-Barre Syndrome (GBS) has occurred within 6 weeks of previous influenza vaccination, the decision to give AFLURIA should be based on careful consideration of the potential benefits and risks.
If AFLURIA is administered to immunocompromised persons, including those receiving immunosuppressive therapy, the immune response may be diminished. AFLURIA should be given to pregnant women only if necessary. AFLURIA has not been evaluated in nursing mothers. It is not known whether AFLURIA can be excreted in human milk following immunization. Because many drugs are excreted in human milk, caution should be exercised when AFLURIA is administered to a nursing woman.
Antibody responses in persons 65 years of age and older were lower after administration of AFLURIA as compared to younger adult subjects. In children 5 through 17 years of age, the most common injection-site reactions observed in clinical studies with AFLURIA were pain, redness and swelling. The most common systemic adverse events were headache, myalgia, malaise and fever. In adults 18 through 64 years of age, the most common injection-site adverse reactions observed in clinical studies with AFLURIA were tenderness and pain. The most common systemic adverse reactions observed were headache, malaise and muscle aches.
In adults 65 years of age and older, the most common injection-site adverse reactions observed in clinical studies with AFLURIA were tenderness and pain. Vaccination with AFLURIA may not protect all individuals. Before administering AFLURIA, please read the Prescribing Information. About bioCSL Inc. bioCSL Inc. is
bioCSL is a leading provider of essential vaccines, pharmaceuticals and diagnostic reagents. For over 50 years, bioCSL has manufactured seasonal and pandemic influenza vaccines. It operates one of the world's largest influenza vaccine manufacturing facilities in
Visit bioCSL Inc. at www.biocsl-us.com
Keywords for this news article include: Pediatrics, bioCSL Inc, Public Health, Viral Vaccines, Influenza Vaccines, Biological Products.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC
Hispanic #1 Breaking News for Entrepreneurs, Professionals and Small Business Owners - HispanicBusiness.com
SEPTEMBER 22, 2014
|Customer Service||Policy||Advertise||Site Tools|
|HispanicBusiness Services||Editorial Guidelines||Ad Specifications||Magazine Archive|
|List Rental Agreement||About Us||Media Kits||Post Your Event|
|HireDiversity Job Search||Editorial Calendar||Research|
© 2014 HispanicBusiness Inc. All Rights Reserved.